THE DEMOGRAPHIC PROFILE OF HIV-1 DRUG RESISTANCE PROTEASE/ REVERSE TRANSCRIPTASE (PR/RT) CASES IN MALAYSIA FROM 2020-2022 by S. Abdullah, K. Kamel, F.A. Suib, R. Mohd Zain

“…Then it is analysed with reference to Stanford HIV Drug Resistance Database. Patients’ forms are screened for clinical profile and demographic distribution. …”
Get full text

Probe Capture Enrichment Methods for HIV and HCV Genome Sequencing and Drug Resistance Genotyping by Chantal Munyuza, Hezhao Ji, Emma R. Lee

“…Over the years, sophisticated sequencing technologies such as next-generation sequencing (NGS) have emerged and been utilized to monitor the spread of HIV drug resistance (HIVDR), identify HIV drug resistance mutations, and characterize transmission dynamics. …”
Get full text

Use of a mutation-specific genotyping method to assess for HIV-1 drug resistance in antiretroviral-naïve HIV-1 Subtype C-infected patients in Botswana [version 2; peer review: 2 ap... by Dorcas Maruapula, Iain J. MacLeod, Sikhulile Moyo, Rosemary Musonda, Kaelo Seatla, Kesaobaka Molebatsi, Melvin Leteane, Max Essex, Simani Gaseitsiwe, Christopher F. Rowley

“…The high costs of available HIV drug resistance assays prohibit their routine usage in resource-limited settings. …”
Get full text

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation by Paredes, R, Tzou, PL, Van Zyl, G, Barrow, G, Camacho, R, Carmona, S, Grant, PM, Gupta, RK, Hamers, RL, Harrigan, PR, Jordan, MR, Kantor, R, Katzenstein, DA, Kuritzkes, DR, Maldarelli, F, Otelea, D, Wallis, CL, Schapiro, JM, Shafer, RW

“…</p> <h4>Conclusions</h4> <p>The HIVDB GRT-IS was updated through a collaborative process to reflect changes in HIV drug resistance knowledge, treatment guidelines, and expert opinion. …”

Potential Anti-HIV Agents from Marine Resources: An Overview by Thanh-Sang Vo, Se-Kwon Kim

“…However, emergence of HIV drug resistance, side effects and the necessity for long-term anti-HIV treatment are the main reasons for failure of anti-HIV therapy. …”
Get full text

FIVE-YEAR EXPERIENCE OF HIGHLY ACTIVITY ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV-INFECTION by V. B. Denisenko, E. N. Simovanyan

“…For increase of therapy efficiency it is necessary lopinavir/ritonavir to include in HAART schemes, and also to carry out selection of preparations taking into account HIV drug resistance.…”
Get full text

Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya by Inzaule, S, Hamers, R, Mukui, I, Were, K, Owiti, P, Kwaro, D, de Wit, T, Zeh, C

“…We performed a countrywide assessment of HIV drug resistance among 123 patients with virological failure on second-line antiretroviral therapy (ART) in Kenya. …”

HIV virologic response, patterns of drug resistance mutations and correlates among adolescents and young adults: A cross-sectional study in Tanzania by Joan Rugemalila, Doreen Kamori, Peter Kunambi, Mucho Mizinduko, Amon Sabasaba, Salim Masoud, Frank Msafiri, Sabina Mugusi, Rita Mutagonda, Linda Mlunde, Davis Amani, Erick Mboya, Macdonald Mahiti, George Ruhago, Jeremiah Mushi, Veryeh Sambu, George Mgomella, Boniface Jullu, Werner Maokola, Prosper Njau, Beatrice Mutayoba, Godfrey Barabona, Takamasa Ueno, Andrea Pembe, Tumaini Nagu, Bruno Sunguya, Said Aboud

“…<h4>Background</h4> The emergence of HIV drug resistance mutations (DRMs) is of significant threat to achieving viral suppression (VS) in the quest to achieve global elimination targets. …”
Get full text

HIV virologic response, patterns of drug resistance mutations and correlates among adolescents and young adults: A cross-sectional study in Tanzania. by Joan Rugemalila, Doreen Kamori, Peter Kunambi, Mucho Mizinduko, Amon Sabasaba, Salim Masoud, Frank Msafiri, Sabina Mugusi, Rita Mutagonda, Linda Mlunde, Davis Amani, Erick Mboya, Macdonald Mahiti, George Ruhago, Jeremiah Mushi, Veryeh Sambu, George Mgomella, Boniface Jullu, Werner Maokola, Prosper Njau, Beatrice Mutayoba, Godfrey Barabona, Takamasa Ueno, Andrea Pembe, Tumaini Nagu, Bruno Sunguya, Said Aboud

“…<h4>Background</h4>The emergence of HIV drug resistance mutations (DRMs) is of significant threat to achieving viral suppression (VS) in the quest to achieve global elimination targets. …”
Get full text

High prevalence of pre-treatment and acquired HIV-1 drug resistance mutations among non-citizens living with HIV in Botswana by Patrick T. Mokgethi, Patrick T. Mokgethi, Wonderful T. Choga, Wonderful T. Choga, Wonderful T. Choga, Dorcas Maruapula, Natasha O. Moraka, Natasha O. Moraka, Kaelo K. Seatla, Ontlametse T. Bareng, Ontlametse T. Bareng, Doreen D. Ditshwanelo, Graceful Mulenga, Terence Mohammed, Pearl M. Kaumba, Pearl M. Kaumba, Moses Chihungwa, Tafireyi Marukutira, Tafireyi Marukutira, Tafireyi Marukutira, Sikhulile Moyo, Sikhulile Moyo, Sikhulile Moyo, Sikhulile Moyo, Catherine K. Koofhethile, Catherine K. Koofhethile, Diana Dickinson, Sununguko W. Mpoloka, Simani Gaseitsiwe, Simani Gaseitsiwe

“…Viral RNA isolated from plasma samples were genotyped for HIV drug resistance (HIVDR) using Sanger sequencing. Major known HIV drug resistance mutations (DRMs) in the pol region were determined using the Stanford HIV Drug Resistance Database. …”
Get full text

Molecular epidemiology and reverse transcript ase (RT) and protease inhibitors (PR) resistance genotyping of human immunodeficiency virus (HIV) in Kelantan by Rafidah Hanim, Shueb

“…Genotyping Tool while ARV resistance mutations were analysed using Stanford HIV Drug Resistance Database.…”
Get full text

Characterisation of circulatiing HIV-1 subtypes and drug resistance-associated mutations in protease and reverse transcriptase genes among HIV-1 patients in Kelantan by Tengku Mohd Ariffin, Tengku Ahmad Akram

“…Meanwhile, according to Stanford HIV drug resistance database, 79.7% of patients currently receiving treatment carrying HIV-1 containing acquired RAMs against NRTI, NNRTI and PI. …”
Get full text

HIV-1C in-House RNA-Based Genotyping Assay for Detection of Drug Resistance Mutations in Samples with Low-Level Viral Loads by Bareng OT, Choga WT, Maphorisa ST, Seselamarumo S, Seatla KK, Mokgethi PT, Maruapula D, Mogwele ML, Ditshwanelo D, Moraka NO, Gobe I, Motswaledi MS, Makhema JM, Musonda R, Shapiro R, Essex M, Novitsky V, Moyo S, Gaseitsiwe S

“…We here assess the performance of an in-house HIV drug resistance genotyping assay using plasma for the detection of DRM at LLV.Methods: We used a total of 96 HIV plasma samples from the population-based Botswana Combination Prevention Project (BCPP). …”
Get full text

HIV protease resistance mutations in patients receiving second-line antiretroviral therapy in Libreville, Gabon by Guy Francis Nzengui-Nzengui, Gaël Mourembou, Hervé M’boyis-Kamdem, Ayawa Claudine Kombila-Koumavor, Angélique Ndjoyi-Mbiguino

“…This study aims to determine the profiles of HIV drug resistance mutations related to protease inhibitors in Gabon. …”
Get full text

Epidemiological characteristics of HIV transmission in southeastern China from 2015 to 2020 based on HIV molecular network by Zhenghua Wang, Dong Wang, Liying Lin, Yuefeng Qiu, Chunyan Zhang, Meirong Xie, Xiaoli Lu, Qiaolin Lian, Pingping Yan, Liang Chen, Yi Feng, Hui Xing, Wei Wang, Shouli Wu, Shouli Wu

“…The dominant HIV subtypes were CRF01_AE (41.7%) and CRF07_BC (38.3%) in 2015 and CRF07_BC (53. 3%) and CRF01_AE (29.1%) in 2020, and the prevalence of HIV drug resistance was 4.2% in 2015 and 5.3% in 2020. Sequences of CRF07_BC formed the largest HIV-1 transmission cluster at a genetic distance threshold of both 1.5 and 0.5%. …”
Get full text

The global burden of HIV-1 drug resistance in the past 20 years by Maurizio Zazzi, Hui Hu, Mattia Prosperi

“…In this work, we queried two of the largest public HIV sequence repositories in the world—Los Alamos and Stanford HIVdb—to derive global prevalence, time trends and geodemographic predictors of HIV drug resistance. Different genotypic interpretation systems were used to ascertain resistance to reverse transcriptase and protease inhibitors. …”
Get full text

Molecular epidemiological analysis of HIV-1 in Kazakhstan in 2009-2013 by I. A. Lapovok, V. Y. Laga, E. V. Kazennova, A. V. Vasilyev, N. V. Dzissyuk, A. K. Utegenova, A. T. Abishev, M. S. Tukeev, M. R. Bobkova

“…The data on low prevalence (3%) of HIV drug resistance mutations in native patients were obtained.…”
Get full text

Understanding patterns of HIV multi-drug resistance through models of temporal and spatial drug heterogeneity by Alison F Feder, Kristin N Harper, Chanson J Brumme, Pleuni S Pennings

“…These therapies should prevent HIV drug resistance evolution, because one or more drugs suppress any partially resistant viruses. …”
Get full text

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. by Fidler, S, Oxenius, A, Brady, M, Clarke, J, Cropley, I, Babiker, A, Zhang, H, Price, D, Phillips, R, Weber, J

“…Two of the 45 individuals had evidence of genotypic HIV drug resistance at baseline, and none developed new mutations following therapy. …”

Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. by Fidler, S, Oxenius, A, Brady, M, Clarke, J, Cropley, I, Babiker, A, Zhang, H, Price, D, Phillips, R, Weber, J

“…Two of the 45 individuals had evidence of genotypic HIV drug resistance at baseline, and none developed new mutations following therapy. …”